MorphoSys AG · ISIN: DE0006632003 · EQS - Company News

Merger Squeeze-Out of MorphoSys Minority Shareholders Approved at 2024 Annual General Meeting

Media Release Planegg/Munich, Germany, August 27, 2024   Merger Squeeze-Out of MorphoSys Minority Shareholders Approved at 2024 Annual General Meeting MorphoSys AG today announced that its shareholders approved all resolutions proposed by the company’s Management Board and Supervisory Board at its 2024 Annual General Meeting. This included the transfer of MorphoSys’ minority shareholders’ shares to Novartis BidCo Germany AG (hereinafter referred to as “Novartis”), the company’s majority share...

XETR:MOR Price indication powered by TradingView

About the publication

Corporate Insights - Short Sales, Director's Dealings, Sentiment Indicators - THE info hub for the informed investor

Smart tools for smart investors can be found in our Tools section

Corporate News MorphoSys AG

In this overview you can view company news in the chronological order of publication. The source information comes from EQS News, the leading European news distributor. The most recent news item is listed first.
Back to Corporate News Overview
This might be interesting for you as well
Analyst Ratings (0)
Directors Dealings (7)
Short Selling (DE) (39)
Short Selling (UK) (0)
27 August 2024 04:00PM
Merger Squeeze-Out of MorphoSys Minority Shareholders Approved at 2024 Annual General Meeting
DE0006632003
Media Release Planegg/Munich, Germany, August 27, 2024   Merger Squeeze-Out of MorphoSys Minority Shareholders Approved at 2024 Annual General Meeting MorphoSys AG today announced that its shareholders approved all resolutions proposed by the company’s Management Board and Supervisory Board at its 2024 Annual General Meeting. This included the t...
MorphoSys AG
About the publication
05 August 2024 07:30AM
MorphoSys Completes Voluntary Delisting from the Frankfurt Stock Exchange and Nasdaq Global Market
DE0006632003
Media Release Planegg/Munich, Germany, August 5, 2024   MorphoSys Completes Voluntary Delisting from the Frankfurt Stock Exchange and Nasdaq Global Market   MorphoSys AG today announced that it has completed the voluntary delisting of its shares from the Frankfurt Stock Exchange and its American Depositary Shares (“ADSs”) from the Nasdaq Global ...
MorphoSys AG
About the publication
12 July 2024 10:02PM
MorphoSys Announces Voluntary Delisting from the Nasdaq Global Market
DE0006632003
Media Release Planegg/Munich, Germany, July 12, 2024   MorphoSys Announces Voluntary Delisting from the Nasdaq Global Market   MorphoSys AG (FSE: MOR; NASDAQ: MOR) today announced that it has formally notified the Nasdaq Stock Market of its intention to voluntarily delist its American Depositary Shares (“ADSs”) from the Nasdaq Global Market an...
MorphoSys AG
About the publication
12 July 2024 02:34PM
Merger Squeeze-out Cash Compensation Determined at EUR 68.00
DE0006632003
Publication of an inside information according to Article 17 para. 1 of the Regulation (EU) No. 596/2014 Key word(s): Squeeze Out Planegg/Munich, Germany, July 12, 2024   Ad hoc: Merger Squeeze-out Cash Compensation Determined at EUR 68.00   MorphoSys AG (FSE: MOR; NASDAQ: MOR) announces that Novartis BidCo Germany AG submitted a specified re...
MorphoSys AG
About the publication
20 June 2024 08:25AM
MorphoSys and Novartis Sign Delisting Agreement and Intend to Implement a Merger Squeeze-out of MorphoSys’ Minority Shareholders
DE0006632003
Media Release Planegg/Munich, Germany, June 20, 2024   MorphoSys and Novartis Sign Delisting Agreement and Intend to Implement a Merger Squeeze-out of MorphoSys’ Minority Shareholders   MorphoSys AG (FSE: MOR; NASDAQ: MOR) today announced that the company has entered into a delisting agreement with Novartis BidCo AG and Novartis AG following t...
MorphoSys AG
About the publication
20 June 2024 08:06AM
Novartis BidCo Germany AG Intends to Implement a Merger Squeeze-out of MorphoSys AG’s Minority Shareholders
DE0006632003
Publication of an inside information according to Article 17 para. 1 of the Regulation (EU) No. 596/2014 Key word(s): Squeeze Out Planegg/Munich, Germany, June 20, 2024     Ad hoc: Novartis BidCo Germany AG Intends to Implement a Merger Squeeze-out of MorphoSys AG’s Minority Shareholders MorphoSys AG (FSE: MOR; NASDAQ: MOR) announces that Nov...
MorphoSys AG
About the publication
20 June 2024 08:06AM
Novartis BidCo Germany AG Intends to Implement a Merger Squeeze-out of MorphoSys AG’s Minority Shareholders
DE0006632003
Publication of an inside information according to Article 17 para. 1 of the Regulation (EU) No. 596/2014 Key word(s): Squeeze Out Planegg/Munich, Germany, June 20, 2024     Ad hoc: Novartis BidCo Germany AG Intends to Implement a Merger Squeeze-out of MorphoSys AG’s Minority Shareholders MorphoSys AG (FSE: MOR; NASDAQ: MOR) announces that Nov...
MorphoSys AG
About the publication
06 June 2024 10:19PM
Arkadius Pichota and Lukas Gilgen appointed to Management Board of MorphoSys AG replacing the current CEO and CFO
DE0006632003
Publication of an inside information according to Article 17 para. 1 of the Regulation (EU) No. 596/2014   Planegg/Munich, Germany, June 6, 2024     Ad hoc: Arkadius Pichota and Lukas Gilgen appointed to Management Board of MorphoSys AG replacing the current CEO and CFO   Following the closing of the takeover offer by Novartis BidCo AG to th...
MorphoSys AG
About the publication
29 April 2024 10:01PM
MorphoSys AG Reports First Quarter 2024 Financial Results
DE0006632003
Media Release Planegg/Munich, Germany, April 29, 2024   MorphoSys AG Reports First Quarter 2024 Financial Results Entered into Business Combination Agreement to be acquired by Novartis for € 68.00 per share in cash, representing a total equity value of € 2.7 billion Received all mandatory antitrust approvals for the proposed acquisition by Novar...
MorphoSys AG
About the publication
24 April 2024 04:40PM
MorphoSys To Present New Phase 3 MANIFEST-2 Data on Pelabresib in Myelofibrosis in Oral Presentation at 2024 ASCO Annual Meeting
DE0006632003
Media Release Planegg/Munich, Germany, April 24, 2024 MorphoSys To Present New Phase 3 MANIFEST-2 Data on Pelabresib in Myelofibrosis in Oral Presentation at 2024 ASCO Annual Meeting Additional ASCO 2024 poster presentation will include new findings from the Phase 2 study of tulmimetostat  MorphoSys AG (FSE: MOR; NASDAQ: MOR) today announced th...
MorphoSys AG
About the publication
11 April 2024 02:38PM
MorphoSys’ Management Board and Supervisory Board Recommend Shareholders Accept Public Takeover Offer by Novartis
DE0006632003
Media Release Planegg/Munich, Germany, April 11, 2024   MorphoSys’ Management Board and Supervisory Board Recommend Shareholders Accept Public Takeover Offer by Novartis   Novartis offers € 68.00 per share in cash, representing a total equity value of € 2.7 billion  Shareholders benefit from attractive premium of 94% and 142% on the volume-weig...
MorphoSys AG
About the publication
22 March 2024 07:30AM
MorphoSys Announces U.S. Antitrust Clearance of Proposed Acquisition by Novartis Under HSR Act
DE0006632003
Media Release Planegg/Munich, Germany, March 22, 2024 MorphoSys Announces U.S. Antitrust Clearance of Proposed Acquisition by Novartis Under HSR Act MorphoSys AG (FSE: MOR; NASDAQ: MOR) today announced the receipt of U.S. antitrust clearance under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (the “HSR Act”) in connection with the pro...
MorphoSys AG
About the publication
13 March 2024 09:01PM
MorphoSys AG Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
DE0006632003
Media Release Planegg/Munich, Germany, March 13, 2024   MorphoSys AG Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update - Entered into Business Combination Agreement to be acquired by Novartis for € 68.00 per share in cash or € 2.7 billion equity value - Sold all tafasitamab rights worldwide to Incyte - P...
MorphoSys AG
About the publication
07 March 2024 10:03PM
Invitation to MorphoSys’ Full Year Results 2023 Conference Call on March 14, 2024
DE0006632003
Conference Call Alert Planegg/Munich, Germany, March 07, 2024   Invitation to MorphoSys’ Full Year Results 2023 Conference Call on March 14, 2024   MorphoSys AG (FSE: MOR; NASDAQ: MOR) will publish its results for the financial year 2023 on March 13, 2024, at 09:00 pm CET (08:00 pm GMT; 04:00 pm EDT). MorphoSys' Management team will host a con...
MorphoSys AG
About the publication
05 February 2024 10:49PM
MorphoSys Enters into Business Combination Agreement to be Acquired by Novartis for € 2.7 Billion Equity Value
DE0006632003
Media Release Planegg/Munich, Germany, February 5, 2024   MorphoSys Enters into Business Combination Agreement to be Acquired by Novartis for € 2.7 Billion Equity Value   Tafasitamab sold to Incyte   Novartis to launch a voluntary public takeover offer for all MorphoSys shares at a price of € 68.00 per share in cash   Shareholders benefi...
MorphoSys AG
About the publication
05 February 2024 10:45PM
MorphoSys AG Enters into Business Combination Agreement to be Acquired by Novartis for € 2.7 Billion Equity Value and into Purchase Agreement with Incyte for the Sale of Tafasitamab
DE0006632003
Publication of an inside information according to Article 17 para. 1 of the Regulation (EU) No. 596/2014   Planegg/Munich, Germany, February 5, 2024     Ad hoc: MorphoSys AG Enters into Business Combination Agreement to be Acquired by Novartis for € 2.7 Billion Equity Value and into Purchase Agreement with Incyte for the Sale of Tafasitamab M...
MorphoSys AG
About the publication
30 January 2024 08:50AM
MorphoSys Reports Preliminary 2023 Monjuvi U.S. Net Product Sales and Gross Margin, Provides 2024 Financial Guidance and Reduces Financial Liability
DE0006632003
Media Release Planegg/Munich, Germany, January 30, 2024   MorphoSys Reports Preliminary 2023 Monjuvi U.S. Net Product Sales and Gross Margin, Provides 2024 Financial Guidance and Reduces Financial Liability  Preliminary 2023 Monjuvi U.S. net product sales of US$ 92.0 million (€ 85.0 million) and preliminary gross margin for Monjuvi U.S. net prod...
MorphoSys AG
About the publication
30 January 2024 08:47AM
MorphoSys AG Reports Preliminary 2023 Monjuvi U.S. Net Product Sales and Gross Margin, Provides 2024 Financial Guidance and Reduces Financial Liability
DE0006632003
Publication of an inside information according to Article 17 para. 1 of the Regulation (EU) No. 596/2014 Planegg/Munich, Germany, January 30, 2024   Ad hoc: MorphoSys AG Reports Preliminary 2023 Monjuvi U.S. Net Product Sales and Gross Margin, Provides 2024 Financial Guidance and Reduces Financial Liability Preliminary 2023 Monjuvi U.S. net pro...
MorphoSys AG
About the publication
08 January 2024 08:00AM
MorphoSys to Present at the 42nd Annual J.P. Morgan Healthcare Conference 
DE0006632003
Media Release Planegg/Munich, Germany, January 8, 2024 MorphoSys to Present at the 42nd Annual J.P. Morgan Healthcare Conference  MorphoSys AG (FSE: MOR; NASDAQ: MOR) today announced that Jean-Paul Kress, M.D., Chief Executive Officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024, at 3:00 p.m. ...
MorphoSys AG
About the publication
14 December 2023 07:06AM
MorphoSys Places New Shares from Cash Capital Increase with Gross Proceeds of Approximately EUR 102.7 Million
DE0006632003
NOT FOR DISTRIBUTION IN OR INTO THE UNITED STATES OF AMERICA OR AUSTRALIA, SOUTH AFRICA, JAPAN OR IN ANY OTHER JURISDICTION IN WHICH, OR TO PERSONS IN ANY JURISDICTION TO WHOM, SUCH DISTRIBUTION WOULD BE PROHIBITED BY APPLICABLE LAW Media Release Planegg/Munich, Germany, December 14, 2023   MorphoSys Places New Shares from Cash Capital Increase...
MorphoSys AG
About the publication
14 December 2023 07:03AM
MorphoSys AG Places New Shares From Cash Capital Increase with Gross Proceeds Of Approximately EUR 102.7 million
DE0006632003
Publication of an inside information according to Article 17 para. 1 of the Regulation (EU) No. 596/2014 Planegg/Munich, Germany, December 14, 2023   Ad hoc: MorphoSys AG Places New Shares From Cash Capital Increase with Gross Proceeds Of Approximately EUR 102.7 million   MorphoSys AG (FSE: MOR; NASDAQ: MOR) (the “Company”) resolved to increase...
MorphoSys AG
About the publication
13 December 2023 10:01PM
MorphoSys AG Launches Cash Capital Increase by way of Accelerated Bookbuilding Process
DE0006632003
Publication of an inside information according to Article 17 para. 1 of the Regulation (EU) No. 596/2014 Planegg/Munich, Germany, December 13, 2023   Ad hoc: MorphoSys AG Launches Cash Capital Increase by way of Accelerated Bookbuilding Process   MorphoSys AG (FSE: MOR; NASDAQ: MOR) (the “Company”) announces that its Management Board, with the...
MorphoSys AG
About the publication
11 December 2023 01:31AM
MorphoSys’ Pelabresib Improves All Four Hallmarks of Myelofibrosis in Phase 3 MANIFEST-2 Study 
DE0006632003
Media Release Planegg/Munich, Germany, December 10, 2023 MorphoSys’ Pelabresib Improves All Four Hallmarks of Myelofibrosis in Phase 3 MANIFEST-2 Study  Pelabresib and ruxolitinib combination significantly reduced spleen size, with an SVR35 response rate nearly double that of placebo plus ruxolitinib Showed a strong positive trend in reducing ...
MorphoSys AG
About the publication
20 November 2023 10:29PM
MorphoSys’ Phase 3 Study of Pelabresib in Myelofibrosis Demonstrates Statistically Significant Improvement in Spleen Volume Reduction and Strong Positive Trend in Symptom Reduction
DE0006632003
Media Release Planegg/Munich, Germany, November 20, 2023   MorphoSys’ Phase 3 Study of Pelabresib in Myelofibrosis Demonstrates Statistically Significant Improvement in Spleen Volume Reduction and Strong Positive Trend in Symptom Reduction MANIFEST-2 met primary endpoint, nearly doubling SVR35 response rate (66% versus 35%)  The key secondary ...
MorphoSys AG
About the publication
20 November 2023 10:27PM
MorphoSys’ Phase 3 Study of Pelabresib in Myelofibrosis Demonstrates Statistically Significant Improvement in Spleen Volume Reduction and Strong Positive Trend in Symptom Reduction
DE0006632003
Publication of an inside information according to Article 17 para. 1 of the Regulation (EU) No. 596/2014 Planegg/Munich, Germany, November 20, 2023 Ad hoc: MorphoSys’ Phase 3 Study of Pelabresib in Myelofibrosis Demonstrates Statistically Significant Improvement in Spleen Volume Reduction and Strong Positive Trend in Symptom Reduction MANIFEST-2...
MorphoSys AG
About the publication
15 November 2023 10:01PM
MorphoSys AG Reports First Nine Months and Third Quarter 2023 Financial Results
DE0006632003
Media Release Planegg/Munich, Germany, November 15, 2023   MorphoSys AG Reports First Nine Months and Third Quarter 2023 Financial Results Phase 3 MANIFEST-2 topline results expected by the end of November, with detailed findings in oral presentation at ASH 2023 Monjuvi® U.S. net product sales of US$ 23.4 million (€ 21.5 million) for the third q...
MorphoSys AG
About the publication
09 November 2023 10:03PM
Invitation to MorphoSys’ Third Quarter and First Nine Months 2023 Financial Results Conference Call on November 16, 2023
DE0006632003
Conference Call Alert Planegg/Munich, Germany, November 09, 2023   Invitation to MorphoSys’ Third Quarter and First Nine Months 2023 Financial Results Conference Call on November 16, 2023   MorphoSys AG (FSE: MOR; NASDAQ: MOR) will publish its results for the third quarter and first nine months 2023 on November 15, 2023, at 10:00 pm CET (09:00 ...
MorphoSys AG
About the publication
02 November 2023 02:05PM
MorphoSys To Showcase Phase 3 MANIFEST-2 Data on Pelabresib in Myelofibrosis in Oral Presentation at 2023 ASH Annual Meeting
DE0006632003
Media Release Planegg/Munich, Germany, November 2, 2023   MorphoSys To Showcase Phase 3 MANIFEST-2 Data on Pelabresib in Myelofibrosis in Oral Presentation at 2023 ASH Annual Meeting Following topline results expected in the coming weeks, the oral session at ASH 2023 in December will provide detailed findings from MANIFEST-2 Investor event foc...
MorphoSys AG
About the publication
25 October 2023 10:50AM
MorphoSys Reports Preliminary Q3 2023 Monjuvi U.S. Sales and Gross Margin, and Updates Financial Guidance for 2023
DE0006632003
Planegg/Munich, Germany, October 25, 2023   MorphoSys Reports Preliminary Q3 2023 Monjuvi U.S. Sales and Gross Margin, and Updates Financial Guidance for 2023   Preliminary Q3 2023 Monjuvi U.S. net product sales of US$ 23.4 million (€ 21.5 million) Preliminary Gross Margin for Monjuvi U.S. net product sales for Q3 2023 of 65% Anticipate full y...
MorphoSys AG
About the publication
25 October 2023 10:48AM
MorphoSys AG Reports Preliminary Q3 2023 Monjuvi U.S. Sales and Gross Margin, and Updates Financial Guidance for 2023
DE0006632003
Publication of an inside information according to Article 17 para. 1 of the Regulation (EU) No. 596/2014   Planegg/Munich, Germany, October 25, 2023     Ad hoc: MorphoSys AG Reports Preliminary Q3 2023 Monjuvi U.S. Sales and Gross Margin, and Updates Financial Guidance for 2023   Preliminary Q3 2023 Monjuvi U.S. net product sales of US$ 23.4...
MorphoSys AG
About the publication
12 September 2023 10:01PM
MorphoSys Receives U.S. FDA Fast Track Designation for Tulmimetostat in Endometrial Cancer
DE0006632003
Media Release Planegg/Munich, Germany, September 12, 2023   MorphoSys Receives U.S. FDA Fast Track Designation for Tulmimetostat in Endometrial Cancer Tulmimetostat follows pelabresib (2018) and tafasitamab (2014) as the company’s third clinical program to receive Fast Track designation MorphoSys AG (FSE: MOR; NASDAQ: MOR) today announced tha...
MorphoSys AG
About the publication
09 August 2023 10:01PM
MorphoSys AG Reports Second Quarter and First Half 2023 Financial Results
DE0006632003
Media Release Planegg/Munich, Germany, August 9, 2023   MorphoSys AG Reports Second Quarter and First Half 2023 Financial Results Monjuvi® U.S. net product sales of US$ 23.6 million (€ 21.7 million) for the second quarter of 2023 Enrollment of Phase 3 MANIFEST-2 study of pelabresib in first-line myelofibrosis is complete, with topline data expec...
MorphoSys AG
About the publication
03 August 2023 10:03PM
Invitation to MorphoSys’ Second Quarter and First Half 2023 Financial Results Conference Call on August 10, 2023
DE0006632003
Conference Call Alert Planegg/Munich, Germany, August 03, 2023   Invitation to MorphoSys’ Second Quarter and First Half 2023 Financial Results Conference Call on August 10, 2023   MorphoSys AG (FSE: MOR; NASDAQ: MOR) will publish its results for the second quarter and first half 2023 on August 09, 2023, at 10:00 pm CEST (09:00 pm BST; 04:00 pm E...
MorphoSys AG
About the publication
14 June 2023 08:39AM
MorphoSys to Host Virtual Investor Call with Key Opinion Leaders Focused on Pelabresib on June 21, 2023
DE0006632003
Media Release Planegg/Munich, Germany, June 14, 2023   MorphoSys to Host Virtual Investor Call with Key Opinion Leaders Focused on Pelabresib on June 21, 2023 MorphoSys AG (FSE: MOR; NASDAQ: MOR) will host a virtual investor event on Wednesday, June 21, at 9:00 a.m. EDT / 3:00 p.m. CEST. During the event, Jean-Paul Kress, M.D., MorphoSys’ Chi...
MorphoSys AG
About the publication
14 June 2023 08:39AM
MorphoSys to Host Virtual Investor Call with Key Opinion Leaders Focused on Pelabresib on June 21, 2023
DE0006632003
Media Release Planegg/Munich, Germany, June 14, 2023   MorphoSys to Host Virtual Investor Call with Key Opinion Leaders Focused on Pelabresib on June 21, 2023 MorphoSys AG (FSE: MOR; NASDAQ: MOR) will host a virtual investor event on Wednesday, June 21, at 9:00 a.m. EDT / 3:00 p.m. CEST. During the event, Jean-Paul Kress, M.D., MorphoSys’ Chi...
MorphoSys AG
About the publication
17 May 2023 10:01PM
MorphoSys AG Reports Outcome of Annual General Meeting 2023
DE0006632003
Media Release Planegg/Munich, Germany, May 17, 2023   MorphoSys AG Reports Outcome of Annual General Meeting 2023 All Proposed Resolutions Approved MorphoSys AG (FSE: MOR; NASDAQ: MOR) announced today that its shareholders approved all resolutions proposed by the Company´s Management and Supervisory Boards at the Company´s virtual Annual Genera...
MorphoSys AG
About the publication
17 May 2023 10:01PM
MorphoSys AG Reports Outcome of Annual General Meeting 2023
DE0006632003
Media Release Planegg/Munich, Germany, May 17, 2023   MorphoSys AG Reports Outcome of Annual General Meeting 2023 All Proposed Resolutions Approved MorphoSys AG (FSE: MOR; NASDAQ: MOR) announced today that its shareholders approved all resolutions proposed by the Company´s Management and Supervisory Boards at the Company´s virtual Annual Genera...
MorphoSys AG
About the publication
11 May 2023 06:39PM
MorphoSys Highlights Potential of Its Mid- to Late-Stage Oncology Pipeline at 2023 ASCO and EHA Annual Meetings
DE0006632003
Media Release Planegg/Munich, Germany, May 11, 2023   MorphoSys Highlights Potential of Its Mid- to Late-Stage Oncology Pipeline at 2023 ASCO and EHA Annual Meetings   MorphoSys AG (FSE: MOR; NASDAQ: MOR) today announced that the latest data on multiple pipeline therapies will be presented during the American Society of Clinical Oncology (ASCO...
MorphoSys AG
About the publication
11 May 2023 06:39PM
MorphoSys Highlights Potential of Its Mid- to Late-Stage Oncology Pipeline at 2023 ASCO and EHA Annual Meetings
DE0006632003
Media Release Planegg/Munich, Germany, May 11, 2023   MorphoSys Highlights Potential of Its Mid- to Late-Stage Oncology Pipeline at 2023 ASCO and EHA Annual Meetings   MorphoSys AG (FSE: MOR; NASDAQ: MOR) today announced that the latest data on multiple pipeline therapies will be presented during the American Society of Clinical Oncology (ASCO...
MorphoSys AG
About the publication
03 May 2023 10:01PM
MorphoSys AG Reports First Quarter 2023 Financial Results
DE0006632003
Media Release Planegg/Munich, Germany, May 03, 2023   MorphoSys AG Reports First Quarter 2023 Financial Results Monjuvi® U.S. net product sales of US$ 20.8 million (€ 19.4 million) for the first quarter of 2023 Enrollment of Phase 3 MANIFEST-2 study of pelabresib in first-line myelofibrosis is complete, with topline data expected by the end of 2...
MorphoSys AG
About the publication
03 May 2023 10:01PM
MorphoSys AG Reports First Quarter 2023 Financial Results
DE0006632003
Media Release Planegg/Munich, Germany, May 03, 2023   MorphoSys AG Reports First Quarter 2023 Financial Results Monjuvi® U.S. net product sales of US$ 20.8 million (€ 19.4 million) for the first quarter of 2023 Enrollment of Phase 3 MANIFEST-2 study of pelabresib in first-line myelofibrosis is complete, with topline data expected by the end of 2...
MorphoSys AG
About the publication
27 April 2023 10:03PM
Invitation to MorphoSys’ First Quarter 2023 Financial Results Conference Call on May 4, 2023
DE0006632003
Conference Call Alert Planegg/Munich, Germany, April 27, 2023   Invitation to MorphoSys’ First Quarter 2023 Financial Results Conference Call on May 4, 2023 MorphoSys AG (FSE: MOR; NASDAQ: MOR) will publish its results for the first quarter 2023 on May 3, 2023 at 10:00 pm CEST (09:00 pm BST; 04:00 pm EDT). MorphoSys' Management team will host a ...
MorphoSys AG
About the publication
27 April 2023 10:03PM
Invitation to MorphoSys’ First Quarter 2023 Financial Results Conference Call on May 4, 2023
DE0006632003
Conference Call Alert Planegg/Munich, Germany, April 27, 2023   Invitation to MorphoSys’ First Quarter 2023 Financial Results Conference Call on May 4, 2023 MorphoSys AG (FSE: MOR; NASDAQ: MOR) will publish its results for the first quarter 2023 on May 3, 2023 at 10:00 pm CEST (09:00 pm BST; 04:00 pm EDT). MorphoSys' Management team will host a ...
MorphoSys AG
About the publication
16 April 2023 09:01PM
MorphoSys and Incyte Announce Five-Year Results of L-MIND Study Showed Prolonged, Durable Responses in Relapsed or Refractory DLBCL Patients Treated with Monjuvi® (tafasitamab-cxix)
DE0006632003
Media Release   MorphoSys and Incyte Announce Five-Year Results of L-MIND Study Showed Prolonged, Durable Responses in Relapsed or Refractory DLBCL Patients Treated with Monjuvi® (tafasitamab-cxix) Results from the Phase 2 L-MIND study were highlighted as a late-breaking oral presentation at the American Association for Cancer Research Annual M...
MorphoSys AG
About the publication
16 April 2023 09:01PM
MorphoSys and Incyte Announce Five-Year Results of L-MIND Study Showed Prolonged, Durable Responses in Relapsed or Refractory DLBCL Patients Treated with Monjuvi® (tafasitamab-cxix)
DE0006632003
Media Release   MorphoSys and Incyte Announce Five-Year Results of L-MIND Study Showed Prolonged, Durable Responses in Relapsed or Refractory DLBCL Patients Treated with Monjuvi® (tafasitamab-cxix) Results from the Phase 2 L-MIND study were highlighted as a late-breaking oral presentation at the American Association for Cancer Research Annual M...
MorphoSys AG
About the publication
04 April 2023 10:01PM
MorphoSys Completes Enrollment of Phase 3 MANIFEST-2 Study of Pelabresib in Myelofibrosis with Topline Results Expected by End of 2023
DE0006632003
Media Release Planegg/Munich, Germany, April 4, 2023   MorphoSys Completes Enrollment of Phase 3 MANIFEST-2 Study of Pelabresib in Myelofibrosis with Topline Results Expected by End of 2023 Enrollment of Phase 3 frontMIND study of tafasitamab in first-line diffuse large B-cell lymphoma is also complete MorphoSys AG (FSE: MOR; NASDAQ: MOR) anno...
MorphoSys AG
About the publication
04 April 2023 10:01PM
MorphoSys Completes Enrollment of Phase 3 MANIFEST-2 Study of Pelabresib in Myelofibrosis with Topline Results Expected by End of 2023
DE0006632003
Media Release Planegg/Munich, Germany, April 4, 2023   MorphoSys Completes Enrollment of Phase 3 MANIFEST-2 Study of Pelabresib in Myelofibrosis with Topline Results Expected by End of 2023 Enrollment of Phase 3 frontMIND study of tafasitamab in first-line diffuse large B-cell lymphoma is also complete MorphoSys AG (FSE: MOR; NASDAQ: MOR) anno...
MorphoSys AG
About the publication
24 March 2023 05:00PM
Repurchase of portion of outstanding convertible bonds due 2025 (ISIN DE000A3H2XW6)
DE0006632003
NOT FOR DISTRIBUTION IN OR INTO, OR TO ANY PERSON LOCATED OR RESIDENT IN, THE UNITED STATES OF AMERICA, ITS TERRITORIES AND POSSESSIONS, ANY STATE OF THE UNITED STATES OF AMERICA OR THE DISTRICT OF COLUMBIA (THE "UNITED STATES"), AUSTRALIA, SOUTH AFRICA, JAPAN OR IN OR INTO ANY OTHER JURISDICTION WHERE SUCH DISTRIBUTION WOULD BE PROHIBITED BY APPLI...
MorphoSys AG
About the publication
More MorphoSys AG related information
Type Total Last Made by Go to
Corporate Research 0 - - Corporate Research
Directors Dealings 7 10th October 2023 Vermeylen, Krisja DD
Short Seller (DE) 39 27th August 2024 Qube Research & Technologies Limited SSR (DE)
Short Seller (UK) 0 - - SSR (UK)
Disclaimer:

The combination of information with graphic elements makes an important contribution to visual orientation and navigation through complex factual topics. Essential content features can be perceived, grasped and contextually processed much faster. 
The figurative marks, logos and other graphic and textual elements used on this website are for illustrative purposes only. All rights to the aforementioned elements are held by their respective owners. They are used without the intention of copyright infringement or intellectual property infringement.

If you believe that copyrights or intellectual property have been infringed by the choice of illustration, please contact us immediately to clarify the issue.

v.07062023 EN